Wealthspire Advisors (New York)’s BioMarin Pharmaceuticals BMRN Stock Holding History

Wealthspire Advisors (New York)’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-412	Closed	-$22.3K	–	1269
2025 Q3	$22.3K	Buy	+412	New	+$23.6K	﹤0.01%	1627
2020 Q2	–	Sell	-10,068	Closed	-$851K	–	304
2020 Q1	$851K	Buy	+10,068	New	+$868K	0.04%	218
2019 Q1	–	Sell	-20	Closed	-$2K	–	144
2018 Q4	$2K	Buy	+20	New	+$1.9K	﹤0.01%	738

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Wealthspire Advisors (New York)'s BMRN Position: Q4 2025 in Review

Wealthspire Advisors (New York) sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2025, closing a stake of 412 shares — an estimated $22.3K sold.

Wealthspire Advisors (New York) first reported a position in BMRN in Q4 2018 and held it in 3 quarters. The position peaked at $851K in Q1 2020. 539 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.

Wealthspire Advisors (New York) reported no remaining BioMarin Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Wealthspire Advisors (New York) sold 412 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $22.3K.
Wealthspire Advisors (New York) first reported a position in BioMarin Pharmaceuticals in Q4 2018 and held it in 3 quarters.
Wealthspire Advisors (New York)'s BioMarin Pharmaceuticals position peaked at $851K in Q1 2020.
539 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.

Based on Wealthspire Advisors (New York)'s 13F filing for Q4 2025, filed 13 Feb 2026.